ArticleSaudi medical journal2025
Prevalence and impact of endocrinopathies on growth in pediatric down syndrome patients: A retrospective analysis.
Article in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence, Spectrum, and Management of Thyroid Dysfunction in Children with Down Syndrome: A Retrospective Study from Southern Saudi Arabia.Children (Basel, Switzerland) · 2025Article
- Association Between Physical Fitness and Quality of Life in Children and Adolescents with Down Syndrome.Children (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the prevalence of endocrinopathies and their impact on growth among pediatric patients with Down syndrome (DS) in the Eastern Region of Saudi Arabia.
methodsThis study utilized a retrospective cross-sectional design and was conducted at the Qatif Central Hospital between January 2015 and December 2022. Data from 358 pediatric patients with DS (aged 0-14 years), including clinical, anthropometric, and laboratory findings, were analyzed. The prevalence rates of endocrinopathies, their association with comorbidities, and their impact on growth metrics were evaluated using statistical methods.
resultsHypothyroidism was the most prevalent endocrinopathy (18.9%), followed by vitamin D deficiency (15.4%). Significant associations were observed between hypothyroidism and obesity (
conclusionEndocrinopathies are common among children with DS and substantially affect growth and health outcomes. Early screening and multidisciplinary management strategies are essential to improve patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.